LL-37
Also known as: Cathelicidin, Human Cathelicidin Antimicrobial Peptide, hCAP18-derived peptide
Overview
LL-37 is human's only known cathelicidin antimicrobial peptide — a naturally occurring immune system defender first isolated in 1995 at Sweden's Karolinska Institute by Agerberth et al. This 37-amino acid peptide represents one of our body's most sophisticated pathogen-fighting tools.
What makes LL-37 particularly noteworthy is its dual nature. Unlike traditional antibiotics that target specific bacterial processes, LL-37 physically disrupts pathogen membranes whilst simultaneously modulating immune responses. It's naturally produced by neutrophils, macrophages, and various tissue cells, serving as a first-line defence at mucosal surfaces.
Research suggests LL-37's broad-spectrum activity against bacteria, fungi, and some viruses. Its unique membrane-disrupting mechanism may make bacterial resistance development less likely — a potential advantage over conventional antibiotics. Laboratory studies suggest possible effects on wound healing by attracting immune cells and encouraging blood vessel formation.
Current evidence comes primarily from laboratory studies and limited human observations. Unlike peptides with extensive clinical data such as [Semaglutide](/peptides/semaglutide) or [Tirzepatide](/peptides/tirzepatide), LL-37 lacks comprehensive human trials. This positions it firmly in experimental territory rather than established therapeutic use, similar to emerging research compounds like [Thymosin Beta-4](/peptides/thymosin-beta-4) and [KPV](/peptides/kpv).
The peptide's complexity extends beyond simple pathogen killing. Research suggests LL-37 can both promote and suppress inflammation depending on context, making it a sophisticated immune modulator rather than a blunt instrument. This nuanced behaviour partly explains why therapeutic applications remain unclear despite promising antimicrobial properties.
For UK users considering peptide research, understanding [UK peptide legality](/learn/uk-peptide-legality) remains crucial. LL-37 is currently classified as a research chemical by MHRA guidelines — available for laboratory use but without approved therapeutic applications. Our [supplier directory](/suppliers) can help locate legitimate research-grade sources, though clinical applications remain unestablished.
Mechanism of Action
LL-37 operates through sophisticated multi-target mechanisms that extend far beyond simple antimicrobial activity, functioning as a comprehensive immune defence tool rather than a single-purpose compound.
The primary antimicrobial mechanism involves electrostatic interactions. LL-37 carries a positive charge that's attracted to negatively charged bacterial membranes. Once bound, the peptide inserts itself into the membrane creating pores that lead to bacterial death (Nizet et al., 2001, Nature Medicine 7:941-946. DOI: 10.1038/90978). This physical disruption mechanism works against gram-positive bacteria, gram-negative bacteria, fungi, and certain viruses — making resistance development potentially less likely than with conventional antibiotics.
Beyond pathogen destruction, LL-37 acts as a cellular communications hub. It binds to formyl peptide receptor-like 1 (FPRL1) on immune cells, sending chemotactic signals that attract neutrophils, monocytes, and T-cells to infection or injury sites (Yang et al., 2000, Journal of Experimental Medicine 192:1069-1074. DOI: 10.1084/jem.192.7.1069). This chemotactic effect helps coordinate immune responses precisely where needed.
The peptide's wound healing properties involve multiple pathways. Laboratory studies suggest LL-37 may promote angiogenesis — the formation of new blood vessels — potentially ensuring injured tissues receive adequate nutrients and oxygen. Simultaneously, research indicates it may encourage epithelial cell migration, potentially helping close wounds efficiently (Heilborn et al., 2003, Journal of Investigative Dermatology 120:379-389. DOI: 10.1046/j.1523-1747.2003.12096.x). These mechanisms share similarities with [BPC-157](/peptides/bpc-157) and [GHK-Cu](/peptides/ghk-cu), though through different molecular pathways.
Perhaps most notably, LL-37 demonstrates context-dependent immunomodulation. Research suggests in acute infections, it may amplify inflammatory responses to clear pathogens quickly. However, in chronic inflammatory conditions, studies indicate it may suppress excessive inflammation, potentially helping restore balance (Lande et al., 2007, Nature 449:564-569. DOI: 10.1038/nature06116). This bidirectional control distinguishes LL-37 from simpler antimicrobial compounds and shares characteristics with other immunomodulatory peptides like [Thymulin](/peptides/thymulin).
The peptide also appears to regulate autophagy — cellular housekeeping processes that remove damaged components. This mechanism potentially contributes to tissue repair and cellular health maintenance, though research remains preliminary compared to established autophagy modulators. Unlike synthetic antimicrobials that target single bacterial processes, LL-37's membrane-disrupting approach may make bacterial adaptation more challenging, as bacteria would need to completely restructure their fundamental membrane architecture.